VM Summit to Explore Risks and Rewards of AI Implementation
NEW YORK—This year will mark the 18th annual Vision Monday Leadership Summit, when influential thought leaders, business experts and vision care professionals will explore the critical decisions that today’s leaders need to wrestle with. This year’s Summit, taking place on March 13, 2024 in New York City, is titled, "What's Your AI Acuity? Sharpening a Vision for the Future” and the program will strive to develop a clear-eyed view of the risks and rewards of AI implementation. Specifically, the Summit will explore the increasingly important role that artificial intelligence is playing in the diagnosis and treatment of ocular disease.
“We’re bringing to the Summit two renowned ophthalmologists, James Tsai, MD and Pearse Keane, MD. They will give Summit attendees an exclusive look at how their teams in the U.S. and U.K., respectively, are using AI to analyze and detect diabetic retinopathy and other sight-threatening conditions,” said Andrew Karp, group editor, lenses and technology, Jobson Medical Information.
Dr. Tsai heads the Center for Ophthalmic Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, the first of its kind in New York and one of the first in the U.S. The Center is dedicated to advancing artificial intelligence in the field of ophthalmology.
This first-of-its-kind initiative strives to transform patient care with more timely diagnosis of eye disease and innovative risk assessment of systemic health conditions. The Center aims to advance clinical innovation in AI-based diagnostic care in ophthalmology and population-based medical care, while advancing the understanding of cardiovascular and neurological conditions that impact patient well-being.
Mount Sinai is incorporating AI into trainee and physician education, research, and the clinical setting for rapid diagnosis of eye diseases and conditions including macular degeneration, diabetic retinopathy, glaucoma, hypertensive retinopathy, systemic conditions and retinal tumors. Early detection and intervention can prevent vision loss and may also prevent heart attack and stroke since several eye conditions are linked to cardiovascular and neurological issues.
“Our department is excited to be at the forefront of ophthalmic innovation in AI and Human Health and play a critical role in validating and implementing the most promising technologies,” said Dr. Tsai, Delafield-Rogers professor and chair of ophthalmology at Icahn Mount Sinai and the Mount Sinai Health System, president of New York Eye and Ear Infirmary of Mount Sinai (NYEE), and inaugural director of the Center. “We anticipate that the Center will help revolutionize and transform population-based health, thereby enhancing quality and equitable care.
“Besides the more timely diagnosis and referral of community-based ocular conditions, we will better predict cardiovascular health in the future since recent research has shown that cardiovascular risk factors can be determined from AI-guided analysis of retinal fundus photographs. No other specialty in medicine allows such an unimpeded view and assessment of the cardiovascular and neurological systems.”
Dr. Pearse Keane leads a pioneering research program at Moorfields Eye Hospital in London that is investigating whether AI can help meet a growing clinical need to better analyze eye scans. Now in its seventh year, the program grew out of a partnership with AI developer DeepMind and now involves Google Health.
“I believe that this technology has the potential to help save the sight of millions of people and I’m proud that Moorfields, the NHS (National Health System) and the UK as a whole, can play a central role,” remarked Dr. Keane.
"The growing use of Artificial Intelligence in both health care and retail portends a seismic shift in how companies are operating," noted Marge Axelrad, SVP editorial director of Vision Monday and VMAIL. "With its vast capabilities, AI is opening up new dimensions and providing previously unimagined insights for customers, patients and employees," she said.
"AI is already creating a new series of questions for decision makers," added Jobson’s Karp. "Among these are: Will AI demand a rethink of products, services and processes? Will leaders and managers come to depend on AI to make decisions about people, productivity and automation? Is AI the great equalizer for independents and entrepreneurs? Will patients trust advice from an algorithm? Will consumers accept recommendations from 'the machine?' What role will critical thinking and human intelligence play as AI spreads?"
The 2024 VM Leadership Summit program will open with a networking breakfast from 8:00 to 9:00 a.m. and the program and lunch will run from 9:00 a.m. to 2:30 p.m. Registration includes the full program, networking breakfast and lunch. Details for registration are posted at www.visionmonday.com/summit. Early bird tickets and registration have a deadline of 11:59 p.m. ET on Dec. 31.
At presstime, Platinum Sponsors of the 2024 VM Leadership Summit include EssilorLuxottica and VSP Vision. The Gold Sponsor is Ocuco.
Look for further information about speakers and the venue which will be posted soon in upcoming VMAIL announcements.